Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Lipid-based Nanoparticles As Pharmaceutical Drug Carriers: From Concepts To Clinic.

A. Puri, Kristin S. Loomis, B. Smith, J. Lee, Amichai Yavlovich, E. Heldman, R. Blumenthal
Published 2009 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
In recent years, various nanotechnology platforms in the area of medical biology, including both diagnostics and therapy, have gained remarkable attention. Moreover, research and development of engineered multifunctional nanoparticles as pharmaceutical drug carriers have spurred exponential growth in applications to medicine in the last decade. Design principles of these nanoparticles, including nanoemulsions, dendrimers, nano-gold, liposomes, drug-carrier conjugates, antibody-drug complexes, and magnetic nanoparticles, are primarily based on unique assemblies of synthetic, natural, or biological components, including but not limited to synthetic polymers, metal ions, oils, and lipids as their building blocks. However, the potential success of these particles in the clinic relies on consideration of important parameters such as nanoparticle fabrication strategies, their physical properties, drug loading efficiencies, drug release potential, and, most importantly, minimum toxicity of the carrier itself. Among these, lipid-based nanoparticles bear the advantage of being the least toxic for in vivo applications, and significant progress has been made in the area of DNA/RNA and drug delivery using lipid-based nanoassemblies. In this review, we will primarily focus on the recent advances and updates on lipid-based nanoparticles for their projected applications in drug delivery. We begin with a review of current activities in the field of liposomes (the so-called honorary nanoparticles), and challenging issues of targeting and triggering will be discussed in detail. We will further describe nanoparticles derived from a novel class of amphipathic lipids called bolaamphiphiles with unique lipid assembly features that have been recently examined as drug/DNA delivery vehicles. Finally, an overview of an emerging novel class of particles (based on lipid components other than phospholipids), solid lipid nanoparticles and nanostructured lipid carriers will be presented. We conclude with a few examples of clinically successful formulations of currently available lipid-based nanoparticles.
This paper references
10.1016/J.JCONREL.2007.11.005
Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
W. Cheng (2008)
10.1007/s11095-007-9514-y
Solid Lipid Nanoparticles as Delivery Systems for Bromocriptine
E. Esposito (2007)
10.1097/CAD.0b013e3282a213ce
Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects
S. Garde (2007)
10.1002/cmdc.200800122
HER‐2‐Targeted Nanoparticle–Affibody Bioconjugates for Cancer Therapy
F. Alexis (2008)
10.1021/LA050871S
Fluid and air-stable lipopolymer membranes for biosensor applications.
Fernando Albertorio (2005)
10.1196/annals.1281.018
HER‐2‐Targeted Antisense Oligonucleotide Results in Sensitization of Head and Neck Cancer Cells to Chemotherapeutic Agents
A. Rait (2003)
Binding of antigen-bearing fluorescent liposomes to the murine myeloma tumor MOPC 315.
L. Leserman (1979)
10.1158/1078-0432.CCR-03-0041
Improved Therapeutic Responses in a Xenograft Model of Human B Lymphoma (Namalwa) for Liposomal Vincristine versus Liposomal Doxorubicin Targeted via Anti-CD19 IgG2a or Fab′ Fragments
P. Sapra (2004)
10.1002/CHIN.200818242
Discovery and Development of Folic‐Acid‐Based Receptor Targeting for Imaging and Therapy of Cancer and Inflammatory Diseases
P. Low (2008)
Use of the post-insertion method for the formation of ligand-coupled liposomes.
T. Allen (2002)
10.1128/IAI.68.1.54-63.2000
Archaeosome Vaccine Adjuvants Induce Strong Humoral, Cell-Mediated, and Memory Responses: Comparison to Conventional Liposomes and Alum
L. Krishnan (2000)
10.1126/science.341.6141.9-p
Drug targeting.
V. Torchilin (2000)
10.1182/BLOOD.V100.2.594
Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid.
X. Q. Pan (2002)
10.1016/S0169-409X(01)00233-2
The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors.
D. Needham (2001)
10.1042/BST0030613
Homing of liposomes to target cells.
G. Gregoriadis (1975)
10.1021/LA035817V
Engineered lipids that cross-link the inner and outer leaflets of lipid bilayers.
M. Halter (2004)
10.1086/515085
U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
A. Meyerhoff (1999)
10.1016/S0006-3495(76)85658-5
Membrane viscoelasticity.
E. Evans (1976)
10.1038/nmat2398
Biodegradable luminescent porous silicon nanoparticles for in vivo applications.
J. Park (2009)
10.1002/(SICI)1097-0215(19990301)80:5<723::AID-IJC16>3.0.CO;2-L
Sterically stabilized anti‐idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B‐cell lymphoma model
Y. Tseng (1999)
10.1038/42432
A biosensor that uses ion-channel switches
B. Cornell (1997)
10.1021/JA00049A040
Tetraether bolaform amphiphiles as models of archaebacterial membrane lipids: Raman spectroscopy, phosphorus-31 NMR, x-ray scattering, and electron microscopy
D. Thompson (1992)
Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.
F. Pastorino (2003)
10.1016/j.ijpharm.2008.06.002
Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells.
Xing-guo Zhang (2008)
10.1016/j.ijbiomac.2008.06.006
The use of solid lipid nanoparticles to target a lipophilic molecule to the liver after intravenous administration to mice.
W. Lu (2008)
Synthesis and characterization of head group modified 1,3 diacetylenic phospholipids
A Singh (1989)
10.1023/B:DRUG.0000026252.86842.e2
A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
K. Gelmon (2004)
10.1016/J.EJPB.2005.03.006
Characterisation of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier.
M. Schubert (2005)
10.1073/PNAS.88.24.11460
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.
D. Papahadjopoulos (1991)
10.1007/S10973-009-0228-8
Design of liposomes containing photopolymerizable phospholipids for triggered release of contents
Amichai Yavlovich (2009)
10.1016/0009-3084(88)90062-X
Structure of polymerizable lipid bilayers. I--1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine, a tubule-forming phosphatidylcholine.
D. Rhodes (1988)
10.1021/bm801127d
Stimuli-responsive polymersomes for programmed drug delivery.
F. Meng (2009)
10.1089/10430349950016357
Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts.
L. Xu (1999)
10.1086/382048
Targeting of parasite-specific immunoliposome-encapsulated doxorubicin in the treatment of experimental visceral leishmaniasis.
S. Mukherjee (2004)
Can ether liposomes be used for oral vaccines
EL Chang (1994)
10.1016/0009-3084(84)90069-0
Synthesis of carbamyl and ether analogs of phosphatidylcholines
K. Agarwal (1984)
10.1016/J.EJPS.2005.10.004
Structural investigations on lipid nanoparticles containing high amounts of lecithin.
M. Schubert (2006)
10.1016/J.JCONREL.2005.07.023
Preparation of solid lipid nanoparticles using a membrane contactor.
C. Charcosset (2005)
10.1021/bc900061v
Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL).
Julia Beuttler (2009)
10.1016/J.ADDR.2007.04.008
Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles.
H. L. Wong (2007)
10.1080/02656730600582956
Hyperthermia mediated liposomal drug delivery
A. M. Ponce (2006)
10.1158/0008-5472.CAN-05-1093
Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
C. Mamot (2005)
10.1016/0163-7827(88)90011-2
The lipids of archaebacteria.
M. De Rosa (1988)
10.1016/j.ijpharm.2008.01.041
Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular erythema side effect in mice.
T. Elbayoumi (2008)
10.1016/S0378-5173(99)00256-2
Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice.
O. Ishida (1999)
10.2174/1567201043334678
Drug delivery systems using immobilized intact liposomes: a comparative and critical review.
Heïdi Brochu (2004)
10.1016/0005-2736(81)90034-1
Modification of phospholipid structure results in greater stability if liposomes in serum.
C. Gupta (1981)
10.1021/BI952000V
Poly(ethylene glycol)--lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine.
J. W. Holland (1996)
10.1158/1535-7163.MCT-05-0543
Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors
H. Shmeeda (2006)
10.1385/1-59259-862-5:389
Cytotoxic tumor targeting with scFv antibody-modified liposomes.
C. Marty (2005)
10.1080/10408430802408639
Lipid Nanotubes: Formation, Templating Nanostructures and Drug Nanocarriers
Yong Zhou (2008)
10.1080/10611860500071292
Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns
T. Göppert (2005)
10.1016/S0168-3659(03)00271-2
Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel.
M. Immordino (2003)
10.1006/BBRC.2000.3456
Wavelength-programmed solute release from photosensitive liposomes.
R. Bisby (2000)
10.1021/AR9703241
Chemical approaches to triggerable lipid vesicles for drug and gene delivery.
Xin Guo (2003)
10.1021/LA0528100
Transitions of organized assemblies in mixed systems of cationic bolaamphiphile and anionic conventional surfactants.
Ting Lu (2006)
10.1021/LA049505J
Application of NMR spectroscopy to the characterization of PEG-stabilized lipid nanoparticles.
M. Garcia-Fuentes (2004)
10.1016/J.ADDR.2007.04.007
Solid lipid nanoparticles as a drug delivery system for peptides and proteins.
A. Almeida (2007)
10.1016/S0005-2736(01)00411-4
Targeting Stealth liposomes in a murine model of human small cell lung cancer.
J. Moreira (2001)
10.1038/sj.gt.3302304
A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene
W. Yu (2004)
10.1016/1357-4310(96)88805-8
Liposomes as delivery agents for medical imaging.
V. Torchilin (1996)
10.1073/pnas.0803728105
Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis
E. Murphy (2008)
Transfersomes: self-optimizing carriers for bioactives.
K. Rai (2008)
10.1002/ADMA.200501092
Selective Construction of Supramolecular Nanotube Hosts with Cationic Inner Surfaces
N. Kameta (2005)
10.1021/JO048167O
Design and synthesis of asymmetric acyclic phospholipid bolaamphiphiles.
Toshitsugu Kai (2005)
10.1016/0005-2760(81)90178-8
Carbamyl analogs of phosphatidylcholines. Synthesis, interaction with phospholipases and permeability behavior of their liposomes.
C. Gupta (1981)
10.1016/0005-2736(94)90160-0
Stability and proton-permeability of liposomes composed of archaeal tetraether lipids.
M. Elferink (1994)
Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes.
L. Xu (2002)
10.1080/0738-859991229170
Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems.
Patel Gb (1999)
10.1016/s0022-1759(03)00339-9
Antibody engineering.
J. Maynard (2000)
In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
D. E. Lopes de Menezes (1998)
10.1016/S0022-2836(65)80093-6
Diffusion of univalent ions across the lamellae of swollen phospholipids.
A. Bangham (1965)
10.1080/10837450600561182
Influence of the Formulation for Solid Lipid Nanoparticles Prepared with a Membrane Contactor
Assma Ahmed El-Harati (2006)
10.1007/978-1-4939-6591-5_9
Elastic liposomes for topical and transdermal drug delivery.
H. Benson (2009)
10.1038/sj.clpt.6100400
Nanoparticles in Medicine: Therapeutic Applications and Developments
L. Zhang (2008)
10.1126/SCIENCE.2781283
Spontaneous vesicle formation in aqueous mixtures of single-tailed surfactants.
E. Kaler (1989)
10.1002/chin.198150105
FORMATION OF STABLE BILAYER ASSEMBLIES IN WATER FROM SINGLE-CHAIN AMPHIPHILES. RELATIONSHIP BETWEEN THE AMPHIPHILE STRUCTURE AND THE AGGREGATE MORPHOLOGY
T. Kunitake (1981)
10.1126/SCIENCE.364652
Design of liposomes for enhanced local release of drugs by hyperthermia.
M. Yatvin (1978)
10.1016/J.BIOMATERIALS.2007.09.037
Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug.
Thomas C. Stover (2008)
10.1128/AAC.36.9.1978
Activity of amphotericin B cholesterol dispersion (Amphocil) in experimental visceral leishmaniasis.
J. Berman (1992)
10.1021/mp900090z
Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery.
Emily Gullotti (2009)
10.1038/nrd2614
Nanoparticle therapeutics: an emerging treatment modality for cancer
M. Davis (2008)
10.1016/J.JBIOTEC.2007.01.040
Novel cationic vesicle platform derived from vernonia oil for efficient delivery of DNA through plant cuticle membranes.
Z. Wiesman (2007)
10.1016/J.CHEMPHYSLIP.2005.02.003
Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer.
Olga Garbuzenko (2005)
10.1002/CHIN.200547273
Recent Advances in Tumor-Targeting Anticancer Drug Conjugates
Stanislav Jaracz (2005)
10.1016/J.BIOPHA.2004.01.007
Nanomedicines for overcoming biological barriers.
M. Alonso (2004)
10.1200/jco.2009.27.15_suppl.7066
Phase I study results of nanomolecular liposomal annamycin in refractory ALL.
R. Shepard (2009)
10.1080/08982100802457377
HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents.
A. Puri (2008)
10.1006/BBRC.1994.1983
Unusual thermal stability of liposomes made from bipolar tetraether lipids.
E. Chang (1994)
10.1080/10717540600739914
Nanostructured Lipid Carriers-Containing Anticancer Compounds: Preparation, Characterization, and Cytotoxicity Studies
M. Bondì (2007)
10.1158/1078-0432.CCR-04-2517
Anti-CD19-Targeted Liposomal Doxorubicin Improves the Therapeutic Efficacy in Murine B-Cell Lymphoma and Ameliorates the Toxicity of Liposomes with Varying Drug Release Rates
T. Allen (2005)
10.1016/j.ejpb.2008.09.003
Lipid nanoparticles for parenteral delivery of actives.
Medha D. Joshi (2009)
10.1080/drd_10_4_245
Preparation and Characterization of Solid Lipid Nanoparticles Containing Cloricromene
M. Bondì (2003)
10.1200/JCO.2001.19.5.1444
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
G. Batist (2001)
10.1007/s10517-006-0069-4
Fusion and endocytosis of anionic liposomes with Ehrlich ascitic carcinoma cells
Yu. A. Goryacheva (2006)
10.1016/J.EJPB.2005.02.006
Protein adsorption patterns on poloxamer- and poloxamine-stabilized solid lipid nanoparticles (SLN).
T. Göppert (2005)
10.1039/B518359F
Formulation of photocleavable liposomes and the mechanism of their content release.
Binita Chandra (2006)
10.1246/BCSJ.74.347
36-Membered Macrocyclic Diether Lipid is Advantageous for Archaea to Thrive under the Extreme Thermal Environments
K. Arakawa (2001)
10.2165/00003495-199700544-00004
Liposomes. Opportunities in drug delivery.
T. Allen (1997)
Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.
A. Gabizon (1997)
10.1016/0378-5173(95)00015-B
Effects of the size and fluidity of liposomes on their accumulation in tumors: A presumption of their interaction with tumors
Kazuko Uchiyama (1995)
10.1016/j.biomaterials.2009.07.038
The use of pH-triggered leaky heterogeneities on rigid lipid bilayers to improve intracellular trafficking and therapeutic potential of targeted liposomal immunochemotherapy.
S. Karve (2009)
10.1200/JCO.2004.10.093
Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response.
A. Levine (2004)
10.1016/j.chemphyslip.2009.08.003
Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes.
Avi Schroeder (2009)
10.1166/JBN.2008.335
Liposomes with Triggered Content Release for Cancer Therapy
A. Alaouie (2008)
10.1016/J.BBAMEM.2006.09.004
Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells.
W. Cheng (2007)
10.1007/s11095-005-7247-3
Immunoliposomes Directed Toward VCAM-1 Interact Specifically with Activated Endothelial Cells—A Potential Tool for Specific Drug Delivery
M. Voinea (2005)
10.1016/j.addr.2008.03.007
Ultrasound mediated delivery of drugs and genes to solid tumors.
V. Frenkel (2008)
Nanostructured Lipid Carriers : A Novel Generation of Solid Lipid Drug Carriers
M. Radtke (2005)
10.1016/0014-5793(83)80185-9
Stability of liposomes in circulation is markedly enhanced by structural modification of their phospholipid component
A. Bali (1983)
10.1016/s0021-9258(19)74542-6
Cytotoxicity of folate-Pseudomonas exotoxin conjugates toward tumor cells. Contribution of translocation domain.
C. P. Leamon (1993)
10.1016/S0006-3495(76)85659-7
Membrane viscoplastic flow.
E. Evans (1976)
Polymerized liposomes : From biophysics to applications. Part II
D. Lasic (2000)
10.1089/10430340252792594
Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery.
L. Xu (2002)
10.1016/j.jconrel.2007.12.018
Potential of solid lipid nanoparticles in brain targeting.
I. P. Kaur (2008)
10.1517/17425247.5.1.25
Liposomal nanomedicines
D. Fenske (2008)
10.1093/JAC/28.SUPPL_B.83
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial.
F. Meunier (1991)
10.1016/j.biomaterials.2008.09.014
The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma.
Zhenghong Xu (2009)
10.1016/J.ADDR.2007.04.012
Nanostructured lipid carriers (NLC) in cosmetic dermal products.
R. Mueller (2007)
10.1021/JM049006F
Synthesis and biological activity of anticancer ether lipids that are specifically released by phospholipase A2 in tumor tissue.
T. Andresen (2005)
10.1097/IAE.0b013e3180dc9360
ABSENCE OF HISTOLOGIC RETINAL TOXICITY OF INTRAVITREAL NANOGOLD IN A RABBIT MODEL
S. Bakri (2008)
10.1093/NAR/GNH049
Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide.
Wei Yu (2004)
10.1016/J.ADDR.2003.12.002
Solid lipid nanoparticles for parenteral drug delivery.
S. Wissing (2004)
10.1021/JM031029R
Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugs.
T. Andresen (2004)
10.1002/CHIN.200914274
Nanomedicine—Challenge and Perspectives
K. Riehemann (2009)
10.1007/s00259-006-0139-x
Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies
T. Elbayoumi (2006)
10.1007/s11095-006-9132-0
Micellar Nanocarriers: Pharmaceutical Perspectives
V. Torchilin (2006)
10.1038/nrc903
Ligand-targeted therapeutics in anticancer therapy
T. Allen (2002)
10.1007/s11095-004-7667-5
A Folate Receptor–Targeted Lipid Nanoparticle Formulation for a Lipophilic Paclitaxel Prodrug
P. J. Stevens (2004)
10.1023/A:1016121319668
A Novel Phase Inversion-Based Process for the Preparation of Lipid Nanocarriers
B. Heurtault (2004)
10.1016/S0009-3084(99)00032-8
Phase behavior of fluorocarbon and hydrocarbon double-chain hydroxylated and galactosylated amphiphiles and bolaamphiphiles. Long-term shelf-stability of their liposomes.
L. Clary (1999)
10.1016/S0378-5173(00)00378-1
Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids.
V. Jenning (2000)
10.1002/cncr.21595
Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia
D. Thomas (2006)
10.1002/ijc.1523
Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti‐tag‐72 single‐chain Fvs
G. Pavlinkova (2001)
10.1002/ANIE.198401001
Routes to Functional Vesicle Membranes without Proteins
J. Fuhrhop (1984)
10.1177/108705719700200104
A New Analytical Device Based on Gated Ion Channels: A Peptide-Channel Biosensor
C. Weiss-Wichert (1997)
10.1007/s10637-006-9002-y
A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma
M. Smylie (2006)
10.1002/JPS.1023
Trends and developments in liposome drug delivery systems.
T. Lian (2001)
DOXIL (pegylated liposomal doxorubicin): clinical update. Abstracts of Papers of the American Chemical Society 1996;211:34
FJ Martin (1996)
10.1021/la800207z
Physicochemical and biological characterization of ceramide-containing liposomes: paving the way to ceramide therapeutic application.
Elena Khazanov (2008)
A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model.
D. Needham (2000)
Lipid-based colloidal carriers for peptide and protein delivery – liposomes versus lipid nanoparticles
S. Martins (2007)
10.1016/S0960-9776(01)80001-1
Liposome technology and the development of Myocet™ (liposomal doxorubicin citrate)
C. Swenson (2001)
10.1080/10428190500052438
The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia
A. Fassas (2005)
Solid lipid nano-particles--a novel carrier system for cosmetics and pharmaceutics
RH Muller (1997)
Exploiting vegetable oils for the delivery of hydrophilic drugs
S. Grinberg (2010)
10.1115/1.3160763
Peptide- and aptamer-functionalized nanovectors for targeted delivery of therapeutics.
Todd O. Pangburn (2009)
10.1016/S0163-7827(03)00032-8
Ligand-targeted liposomal anticancer drugs.
P. Sapra (2003)
In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
A. Gabizon (2003)
10.1021/bc900041f
Synthesis of a labeled RGD-lipid, its incorporation into liposomal nanoparticles, and their trafficking in cultured endothelial cells.
Sonya Cressman (2009)
10.1016/S0939-6411(03)00040-7
The influence of solid lipid nanoparticles on skin hydration and viscoelasticity--in vivo study.
S. Wissing (2003)
10.1042/BST0350061
Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging.
D. Tomalia (2007)
10.1016/S1773-2247(09)50030-5
Supramolecularassemblies for the active drug targeting to the brain
A. Béduneau (2009)
10.2174/156720105774370159
Ligand-targeted liposomes for cancer treatment.
P. Sapra (2005)
10.2174/156720105774370203
Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2.
T. Andresen (2005)
10.1021/LA050091J
Novel cationic amphiphilic derivatives from vernonia oil: synthesis and self-aggregation into bilayer vesicles, nanoparticles, and DNA complexants.
S. Grinberg (2005)
10.1016/j.jconrel.2008.09.079
Self-assembling micelle-like nanoparticles based on phospholipid-polyethyleneimine conjugates for systemic gene delivery.
Y. Ko (2009)
10.1166/JCTN.2007.2385
Non-Covalent Conjugation of Nanoparticles to Antibodies via Electrostatic Interactions—A Computational Model
I. Sidorov (2007)
10.1002/JCB.240280105
Binding of antibodies in liposomes to extracellular matrix antigens
V. Torchilin (1985)
10.1246/CL.1984.1709
HELICAL SUPERSTRUCTURES ARE FORMED FROM CHIRAL AMMONIUM BILAYERS
N. Nakashima (1984)
10.1053/J.SEMINONCOL.2004.08.009
Future directions of liposome- and immunoliposome-based cancer therapeutics.
J. Park (2004)
10.1021/JO962327H
Total Synthesis of Archaeal 36-Membered Macrocyclic Diether Lipid.
T. Eguchi (1997)
10.1248/BPB.30.972
In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP).
K. Atobe (2007)
10.1007/s11095-007-9425-y
Antitumor Effect of Paclitaxel-Loaded PEGylated Immunoliposomes Against Human Breast Cancer Cells
T. Yang (2007)
10.1016/J.BBAMEM.2007.04.016
Aggregation and hemi-fusion of anionic vesicles induced by the antimicrobial peptide cryptdin-4.
Jason E. Cummings (2007)
10.2174/187221108784534081
Recent advances and patents on solid lipid nanoparticles.
K. Sawant (2008)
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
J. Park (2002)
10.1016/j.jconrel.2009.10.002
Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy.
P. Pradhan (2010)
10.1006/BBRC.1999.1206
Fast laser-induced solute release from liposomes sensitized with photochromic lipid: effects of temperature, lipid host, and sensitizer concentration.
R. Bisby (1999)
10.1016/J.JCONREL.2005.03.030
Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic.
X. Xiong (2005)
10.1016/J.BBRC.2004.03.074
Isolation of endothelial cell-specific human antibodies from a novel fully synthetic scFv library.
T. Völkel (2004)
10.1016/0021-9797(80)90316-1
Chemical relaxation and equilibrium studies of association in aqueous solutions of bolaform detergents. 3. Docosane-1,22-bis(trimethylammonium bromide)
R. Zana (1980)
Receptor-mediated uptake of asialoganglioside liposomes: sub-cellular distribution of the liposomal marker in isolated liver cell types.
P. Dasgupta (1985)
10.1161/ATVBAHA.108.165506
Nanotechnology in Medical Imaging: Probe Design and Applications
D. Cormode (2009)
10.1016/S0006-291X(81)80020-4
Polymerized phosphatidyl choline vesicles. Stabilized and controllable time-release carriers.
S. Regen (1981)
10.1021/JA00512A020
Formation of Stable Monolayer Membranes and Related Structures in Dilute Aqueous Solution from Two-Headed Ammonium Amphiphiles
Y. Okahata (1979)
10.1089/HUM.2006.17.117
Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery.
K. Pirollo (2006)
10.1039/B607368A
Monolayer lipid membrane-forming dissymmetrical bolaamphiphiles derived from alginate oligosaccharides.
M. Roussel (2006)
10.1016/0014-5793(95)01193-I
Fast solute release from photosensitive liposomes: an alternative to ‘caged’ reagents for use in biological systems
C. Morgan (1995)
10.3109/08982109909024787
STABILITY OF LIPOSOMES PREPARED FROM THE TOTAL POLAR LIPIDS OF METHANOSARCINA MAZE1 IS AFFECTED BY THE SPECIFIC SALT FORM OF THE LIPIDS
G. B. Patel (1999)
10.1211/jpp.61.08.0004
Evaluation of percutaneous absorption of the repellent diethyltoluamide and the sunscreen ethylhexyl p‐methoxycinnamate‐loaded solid lipid nanoparticles: an in‐vitro study
C. Puglia (2009)
10.1016/J.COLSURFB.2007.01.006
Construction of nanogold hollow balls with dendritic surface as immobilized affinity support for protein adsorption.
J. Liao (2007)
10.1016/j.cbpa.2009.03.022
Folate-targeted therapeutic and imaging agents for cancer.
P. Low (2009)
10.1016/j.bpc.2008.10.006
Dibucaine effects on structural and elastic properties of lipid bilayers.
G. S. Lorite (2009)
10.1517/14712598.8.8.1063
Biofunctionalized targeted nanoparticles for therapeutic applications.
A. Wang (2008)
10.1517/13543780903114168
Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin
T. Boulikas (2009)
10.1080/10428190802007700
A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma
P. Mitchell (2008)
10.1016/S0092-8674(03)00112-0
Membrane Fusion
R. Jahn (2003)
10.2174/156802608785849049
Current dendrimer applications in cancer diagnosis and therapy.
I. Majoros (2008)
10.1016/S0168-3659(01)00326-1
VIP receptors as molecular targets of breast cancer: implications for targeted imaging and drug delivery.
S. Dagar (2001)
10.1021/bp049840y
Preclinical Manufacture of an Anti‐HER2 scFv‐PEG‐DSPE, Liposome‐Inserting Conjugate. 1. Gram‐Scale Production and Purification
David F. Nellis (2005)
10.1006/PHRS.2000.0695
Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats.
A. Fundaró (2000)
10.1211/jpp.59.7.0004
Transferrin‐conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain
Yashwant Gupta (2007)
10.1517/17425247.5.9.1003
Antibody-modified liposomes for cancer chemotherapy.
V. Torchilin (2008)
10.1080/08982100801893929
Liposome fluidity alters interactions between the ganglioside GM1 and cholera toxin B subunit.
James Terrell (2008)
10.1016/j.lungcan.2009.06.017
Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer.
N. Mylonakis (2010)
10.1126/SCIENCE.1095833
Drug Delivery Systems: Entering the Mainstream
T. Allen (2004)
10.1016/j.taap.2009.04.010
Cadmium-containing nanoparticles: perspectives on pharmacology and toxicology of quantum dots.
B. Rzigalinski (2009)
10.1016/S0006-3495(02)75557-4
The depth of porphyrin in a membrane and the membrane's physical properties affect the photosensitizing efficiency.
A. Lavi (2002)
10.1039/B803742F
Controllable biomolecule release from self-assembled organic nanotubes with asymmetric surfaces: pH and temperature dependence.
N. Kameta (2008)
10.1021/JA00268A013
Bolaamphiphiles and Monolayer Lipid Membranes Made from 1,6,19,24-Tetraoxa-3,21-cyclohexatriacontadiene-2,5,20,23-tetrone
Juergen-Hinrich Fuhrhop (1986)
10.1021/LA063542O
Self-assembly and thermal phase transition behavior of unsymmetrical bolaamphiphiles having glucose- and amino-hydrophilic headgroups.
N. Kameta (2007)
10.1016/S0378-5173(02)00682-8
Peptide-targeted PEG-liposomes in anti-angiogenic therapy.
A. P. Janssen (2003)
10.1080/08982100802129372
Influence of Drug-to-Lipid Ratio on Drug Release Properties and Liposome Integrity in Liposomal Doxorubicin Formulations
M. J. W. Johnston (2008)
10.1016/j.bbamem.2008.07.029
pH-sensitive non-phospholipid vesicle and macrophage-like cells: binding, uptake and endocytotic pathway.
L. Di Marzio (2008)
10.1529/BIOPHYSJ.106.102764
Stability and phase separation in mixed monopolar lipid/bolalipid layers.
G. Longo (2007)
10.1158/1078-0432.CCR-04-1770
Systemic Delivery of Liposomal Short-Chain Ceramide Limits Solid Tumor Growth in Murine Models of Breast Adenocarcinoma
Thomas C. Stover (2005)
10.1016/J.COLSURFB.2007.06.011
Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification.
H. Yuan (2007)
10.1039/B106581P
Multilayer structure of an unsymmetrical monolayer lipid membrane with a 'head-to-tail' interface.
M. Masuda (2001)
10.1021/LA990627Z
Bolaamphiphilic Phosphocholines: Structure and Phase Behavior in Aqueous Media
C. D. Meglio (2000)
10.1166/JNN.2006.440
Improved oral delivery of paclitaxel following administration in nanoemulsion formulations.
S. Tiwari (2006)
10.1016/S0378-5173(02)00180-1
Nanostructured lipid matrices for improved microencapsulation of drugs.
R. Mueller (2002)
10.1016/J.JCONREL.2003.08.006
Brain uptake of thiamine-coated nanoparticles.
P. Lockman (2003)
10.1016/0009-3084(87)90008-9
Bolaamphiphiles with mannose- and tetraalkylammonium head groups as coatings for nucleic acids and possible reagents for transfections
J. Fuhrhop (1987)
10.1021/JA00057A069
Molecular monolayer rods and tubules made of .alpha.-(L-lysine),.omega.-(amino) bolaamphiphiles
J. Fuhrhop (1993)
10.1016/0005-2736(86)90006-4
Influence of the phospholipid structure on the stability of liposomes in serum.
K. Agarwal (1986)
10.1002/cncr.24359
Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non‐Hodgkin lymphoma
M. Rodriguez (2009)
10.2165/00003088-200342050-00002
Pharmacokinetics of Pegylated Liposomal Doxorubicin
A. Gabizon (2003)
Solid lipid nanoparticles (SLN) based on binary mixtures of liquid and solid lipids: a (1)H-NMR study.
V. Jenning (2000)
10.1021/mp9000662
Biophysical interactions with model lipid membranes: applications in drug discovery and drug delivery.
Chiranjeevi Peetla (2009)
10.1007/s11060-006-9218-x
A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt®) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study
S. Phuphanich (2006)
10.1016/J.EJPB.2006.10.022
In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
H. L. Wong (2007)
10.2174/156720105774370186
Liposomal targeting of angiogenic vasculature.
R. Schiffelers (2005)
10.1016/S0169-409X(01)00232-0
Phototriggering of liposomal drug delivery systems.
P. Shum (2001)
10.1016/J.NANO.2005.03.002
Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer.
E. Kawasaki (2005)
10.1021/BI962148U
Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
D. Kirpotin (1997)
10.1073/PNAS.88.2.444
Complementary molecular shapes and additivity of the packing parameter of lipids.
V. V. Kumar (1991)
10.1021/BC9801124
Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies.
A. Gabizon (1999)
10.1016/S0005-2736(01)00386-8
A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer.
J. Moreira (2001)
10.1177/0192623307310960
Liposomal Nanomedicines: An Emerging Field
D. Fenske (2008)
10.1016/j.urolonc.2007.03.017
New frontiers in nanotechnology for cancer treatment.
F. Alexis (2008)
10.1016/S1359-6446(00)01594-4
Folate-mediated targeting: from diagnostics to drug and gene delivery.
C. P. Leamon (2001)
10.1038/sj.bmt.1702243
Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial
GJ Timmers (2000)
10.1158/0008-5472.CAN-05-4199
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
D. Kirpotin (2006)
10.1007/s11095-008-9615-2
Solid Lipid Nanoparticles Enhance the Delivery of the HIV Protease Inhibitor, Atazanavir, by a Human Brain Endothelial Cell Line
N. Chattopadhyay (2008)
10.3998/ARK.5550190.0007.407
Synthesis and aggregation behaviour of symmetric glycosylated bolaamphiphiles in water
A. Polidori (2006)
10.1016/S0939-6411(00)00087-4
Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art.
R. Mueller (2000)
10.1016/J.ADDR.2004.02.003
Folate receptor-targeted drugs for cancer and inflammatory diseases.
P. Low (2004)
10.1179/acb.2002.014
THE AMPHOTERICIN B LIPID COMPLEX OR ABELCET: ITS BELGIAN CONNECTION, ITS MODE OF ACTION AND SPECIFICITY : A REVIEW
A. Trouet (2002)
10.1016/S0169-409X(01)00103-X
Roles of lipid polymorphism in intracellular delivery.
I. M. Hafez (2001)
Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives
Melike Üner (2007)
LIPOSOMES : AN INDUSTRIAL VIEW
D. Lasić (1996)
10.1246/CL.2001.440
Highly Thermostable Liposome from 72-Membered Macrocyclic Tetraether Lipid: Importance of 72-Membered Lipid for Archaea to Thrive under Hyperthermal Environments
K. Arakawa (2001)
10.3109/08982100903218900
Cationic vesicles from novel bolaamphiphilic compounds
M. Popov (2010)
10.1007/s00280-009-1132-4
Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models
A. Gabizon (2009)
10.1016/j.cbpa.2005.06.001
Nanovector therapeutics.
M. Ferrari (2005)
10.1158/1078-0432.CCR-08-2392
Tumor-Targeted Nanomedicines: Enhanced Antitumor Efficacy In vivo of Doxorubicin-Loaded, Long-Circulating Liposomes Modified with Cancer-Specific Monoclonal Antibody
T. Elbayoumi (2009)
10.1517/14656566.3.12.1739
Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy
G. Batist (2002)
10.1016/j.chemphyslip.2008.01.006
Synthesis of novel cationic bolaamphiphiles from vernonia oil and their aggregated structures.
S. Grinberg (2008)
10.2217/17435889.4.1.105
Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders.
M. Muthu (2009)
10.1016/J.EJPB.2004.03.026
Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line.
L. Serpe (2004)
10.1016/J.ADDR.2004.01.011
Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates.
A. Gabizon (2004)
10.1021/JA035882R
Aqueous self-assembly of unsymmetric Peptide bolaamphiphiles into nanofibers with hydrophilic cores and surfaces.
Randal C. Claussen (2003)
10.1016/J.PLIPRES.2004.12.001
Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release.
T. Andresen (2005)
10.1021/LA049085Y
Lipid nanotubes and microtubes: experimental evidence for unsymmetrical monolayer membrane formation from unsymmetrical bolaamphiphiles.
Mitsutoshi Masuda (2004)
10.1021/LA001084S
Bolaamphiphilic Single-Chain Bis-Schiff Base Derivatives: Aggregation and Thermal Behavior in Aqueous Solution
X. Wang (2001)
10.1016/0005-2736(93)90105-9
Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases.
G. Haran (1993)
10.1080/10611860802229978
Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer
Kimberley M Laginha (2008)
10.1016/J.BBAMEM.2003.08.011
Preparation and electrochemical behavior of gramicidin-bipolar lipid monolayer membranes supported on gold electrodes.
J-M Kim (2003)
10.1002/9780470110546.CH7
Liposomes: preparation, characterization, and preservation.
D. Lichtenberg (1988)
10.1093/ANNONC/MDL484
Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer.
E. Andreopoulou (2007)
10.1080/10717540601036831
Cellular Association and Cytotoxicity of Doxorubicin-Loaded Immunoliposomes Targeted via Fab' Fragments of an Anti-CD74 Antibody
B. Lundberg (2007)
10.1016/J.TUBE.2004.11.003
Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis.
R. Pandey (2005)
10.1517/17425240902939143
The potential for nanoparticle-based drug delivery to the brain: overcoming the blood–brain barrier
E. Barbu, (2009)
10.1023/A:1012043315093
Cytotoxicity of Solid Lipid Nanoparticles as a Function of the Lipid Matrix and the Surfactant
R. Mueller (2004)
10.1016/j.jconrel.2007.12.017
A review of stimuli-responsive nanocarriers for drug and gene delivery.
Srinivas Ganta (2008)
Nanocarrier Technologies: Frontiers of Nanotherapy
M. Mozafari (2006)
10.1021/jp808079h
Stability and rupture of archaebacterial cell membrane: a model study.
S. Li (2009)
10.1016/S0006-3495(04)74316-7
Spontaneously formed monodisperse biomimetic unilamellar vesicles: the effect of charge, dilution, and time.
M. Nieh (2004)
10.1016/j.chemphyslip.2008.11.005
Liposomes containing alkylated methotrexate analogues for phospholipase A(2) mediated tumor targeted drug delivery.
T. Kaasgaard (2009)
10.2217/17435889.4.2.177
Magnetoliposomes: versatile innovative nanocolloids for use in biotechnology and biomedicine.
S. Soenen (2009)
10.3109/10611869909085495
P0 protein mediated targeting of liposomes to melanoma cells with high level of ICAM-1 expression.
M. R. Jaafari (1999)
10.1007/s11095-008-9768-z
Receptor-Specific Targeting with Liposomes In Vitro Based on Sterol-PEG1300 Anchors
M. Gantert (2008)
10.1158/1078-0432.CCR-08-0159
Design of Folate-Linked Liposomal Doxorubicin to its Antitumor Effect in Mice
A. Yamada (2008)
10.1016/j.biomaterials.2008.07.008
The role of daidzein-loaded sterically stabilized solid lipid nanoparticles in therapy for cardio-cerebrovascular diseases.
Y. Gao (2008)
10.1016/S0169-409X(01)00105-3
Solid lipid nanoparticles: production, characterization and applications.
W. Mehnert (2001)
10.1038/nrd1632
Recent advances with liposomes as pharmaceutical carriers
V. Torchilin (2005)
10.1351/pac200880081703
Oxidation-responsiveness of nanomaterials for targeting inflammatory reactions
V. Khutoryanskiy (2008)
10.1021/bp049839z
Preclinical Manufacture of Anti‐HER2 Liposome‐Inserting, scFv‐PEG‐Lipid Conjugate. 2. Conjugate Micelle Identity, Purity, Stability, and Potency Analysis
David F. Nellis (2005)
10.1039/A809079C
SYNTHESIS AND AGGREGATION OF TWO-HEADED SURFACTANTS BEARING AMINO ACID MOIETIES
S. Franceschi (1999)
10.1002/POLA.23122
Unimolecular micelles and reverse micelles based on hyperbranched polyethers—Comparative study of AB2 + A‐R and A2 + B3 + A‐R type strategies
Animesh Saha (2009)
10.1016/J.IJPHARM.2007.03.022
Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)--effects of formulation parameters on physicochemical stability.
Veerawat Teeranachaideekul (2007)
10.1615/CRITREVTHERDRUGCARRIERSYST.V15.I6.20
Folate-mediated targeting of therapeutic and imaging agents to cancers.
J. Reddy (1998)
10.1016/0005-2736(94)90285-2
Asymmetric black membranes formed by one monolayer of bipolar lipids at the air/water interface.
A. Gliozzi (1994)
10.1016/0005-2736(94)00235-H
Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro.
R. Lee (1995)
10.1111/j.1476-5381.2009.00288.x
Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers
P. Midoux (2009)
10.1002/CHIN.200543213
Design of Photocleavable Lipids and Their Application in Liposomal “Uncorking”.
Binita Chandra (2005)
10.1016/J.JCIS.2004.10.012
Design and characterization of a new drug nanocarrier made from solid-liquid lipid mixtures.
M. Garcia-Fuentes (2005)
10.1093/ANNONC/MDH133
A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers.
M. Mackenzie (2004)
10.1016/J.DESAL.2006.03.455
A membrane contactor for the preparation of solid lipid nanoparticles
C. Charcosset (2006)
10.1016/J.IJPHARM.2006.01.040
Preparation and characteristics of monostearin nanostructured lipid carriers.
F. Hu (2006)



This paper is referenced by
AN ADVANCED NANOTECHNOLOGY FOR CANCER THERAPY: A REVIEW
S. S. Dudhamal (2015)
Involvement of the lysosomal protein NPC1 in the pathogenesis of Huntington's disease
E. Clark (2017)
10.7150/thno.34412
Protein Delivery into the Cell Cytosol using Non-Viral Nanocarriers
Yi-Wei Lee (2019)
10.1039/c8cc03471k
Production of dynamic lipid bilayers using the reversible thiol-thioester exchange reaction.
D. Konetski (2018)
10.3390/ijms18040822
Liposomal Encapsulation for Systemic Delivery of Propranolol via Transdermal Iontophoresis Improves Bone Microarchitecture in Ovariectomized Rats
Benjamin Teong (2017)
The Critical Role of Mechanism-Based Models for Understanding and Predicting Liposomal Drug Loading, Binding and Release Kinetics
Sweta Modi (2013)
10.1007/978-3-030-05569-1_1
Nanomaterials and Plant Potential: An Overview
A. Husen (2019)
10.1039/C8TA09959F
Fabrication of regenerated cellulose nanoparticles by mechanical disintegration of cellulose after dissolution and regeneration from a deep eutectic solvent
J. Sirviö (2019)
10.1016/j.drudis.2018.01.043
Thymoquinone-based nanotechnology for cancer therapy: promises and challenges.
Farah Ballout (2018)
10.3978/J.ISSN.2218-676X.2013.08.05
Externally modulated theranostic nanoparticles.
Cordula Urban (2013)
10.1016/j.biopha.2018.07.084
Application of nanoparticles in percutaneous delivery of active ingredients in cosmetic preparations.
Khadijeh Khezri (2018)
10.1101/2020.01.25.918136
Atomistic Molecular Dynamics Simulations of Trioleoylglycerol – Phospholipid Membrane Systems
M. A. Hammad (2020)
10.1016/j.actbio.2017.08.010
Lipogels responsive to near-infrared light for the triggered release of therapeutic agents.
F. Martín-Saavedra (2017)
OF SURFACTANT-FREE , FLUORESCENT POLY ( LACTIC-CO-GLYCOLIC ) ACID NANOPARTICLES TARGETED TO INTERCELLULAR ADHESION MOLECULE-1
Zois Tsinas (2015)
10.1021/la3011663
Triggered release of molecules across droplet interface bilayer lipid membranes using photopolymerizable lipids.
S. Punnamaraju (2012)
10.7150/thno.39847
Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues
B. Kevadiya (2020)
10.2174/1573413714666180809120435
Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: A Review of the Effect of Physicochemical Formulation Factors in the Optimization Process, Different Preparation Technique, Characterization, and Toxicity
G. Poovi (2019)
10.1021/mp300319m
Nanoassembly of surfactants with interfacial drug-interactive motifs as tailor-designed drug carriers.
X. Gao (2013)
10.2174/1389200211314050005
Nanocarriers for anticancer drugs--new trends in nanomedicine.
J. Drbohlavová (2013)
10.2147/IJN.S29661
Exosome mimetics: a novel class of drug delivery systems
S. A. Kooijmans (2012)
10.3109/02652048.2015.1134687
Opioid-based micro and nanoparticulate formulations: alternative approach on pain management
André São Pedro (2016)
10.1039/c8nr02462f
Biocompatible crosslinked β-cyclodextrin nanoparticles as multifunctional carriers for cellular delivery.
S. Datz (2018)
10.1002/bit.26539
From lab to market: An integrated bioprocess design approach for new‐to‐nature biosurfactants produced by Starmerella bombicola
Lisa Van Renterghem (2018)
10.1016/j.biomaterials.2019.119707
Recent advances in porphyrin-based nanocomposites for effective targeted imaging and therapy.
Navid Rabiee (2019)
10.1080/21691401.2017.1290647
Liposome-targeted delivery for highly potent drugs
H. Bardania (2017)
10.1016/j.jconrel.2020.02.020
Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting.
Mukta Agrawal (2020)
10.1142/S0219607714400059
CATIONIC BOLAAMPHIPHILES FOR GENE DELIVERY
Amelia Tan (2014)
10.1007/s11483-015-9416-1
Optimization of Nanoemulsion Fabrication Using Microfluidization: Role of Surfactant Concentration on Formation and Stability
Sibel Uluata (2015)
Preclinical studies of N 3O-toluyl-fluorouracil-loaded lipid-based nanosuspensions in h 22-bearing mice
J. Zhang (2014)
Lipid-based nanoparticles as novel drug delivery systems for antimicrobial agents
A. Rassouli (2019)
10.1007/s11051-013-1498-4
Effect of DOPE and cholesterol on the protein adsorption onto lipid nanoparticles
G. Caracciolo (2013)
10.2174/1574891X113089990038
Applications of nanosystems to anticancer drug therapy (Part II. Dendrimers, micelles, lipid-based nanosystems).
M. E. Ruiz (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar